Skip to content

Bronchiolitis / Paracetamol in infancy: a feasibility study

Is it feasible to undertake a multi-centre randomised control trial of paracetamol versus another anti-pyretic (or placebo) in infants aged between 6 months and 2 years who have been admitted to hospital with a clinical diagnosis of bronchiolitis, to see if there is increased risk of wheezing and atopy by age 3.

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613000309785
Enrollment
36
Registered
2013-03-20
Start date
2013-05-13
Completion date
2013-09-24
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We are trying to see if it is feasible to run a large multi-centre clinical trial to see whether paracetamol use in infancy compared to an alternative (either restricted paracetamol use OR ibuprofen OR placebo) increases the risk of wheezing and atopy by the age of three. We need to find out how acceptable possible alternative to paracetamol would be to parents. We also need to find out whether restricted paracetamol use would actually be statistically different from paracetamol use as usual if we were to offer it as an alternative treatment arm.

Interventions

Study undertaken in 2 parts. Module one: questionnaire administered to all parents / guardians of infants admitted to hospital with bronchiolitis to establish their likelihood of participating in a larger longer term study AND to establish preferred comparator to paracetamol (out of placebo, ibuprofen or paracetamol only according to WHO guidelines). Module one to be completed by December 2013. Module two: Enrollment of 50 participants in Module one into an open label 3-month trial, comparing pa

Study undertaken in 2 parts. Module one: questionnaire administered to all parents / guardians of infants admitted to hospital with bronchiolitis to establish their likelihood of participating in a larger longer term study AND to establish preferred comparator to paracetamol (out of placebo, ibuprofen or paracetamol only according to WHO guidelines). Module one to be completed by December 2013. Module two: Enrollment of 50 participants in Module one into an open label 3-month trial, comparing paracetamol use 'as usual' (in accordance with manufacturers guidelines: 15-20mg /kg, up to 4 times per day, and child to see GP if still problematic after 3-4 days of treatment) with paracetamol only according to WHO guidelines (give 15mg / kg paracetamol only when child has temperature greater than 38.5 degrees AND / OR when child appears to be in significant pain, and only for the shortest period of time). Module Two to be completed by December 2013 All paracetamol is in oral syrup form.

Sponsors

Medical Research Institute of New Zealand
Lead SponsorCharities/Societies/Foundations

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
6 Months to 2 Years
Healthy volunteers
No

Inclusion criteria

Parents / guardians of all infants admitted to the pediatrics ward of Wellington Regional Hospital with a clinical diagnosis of bronchiolitis over the New Zealand Winter season of 2013

Exclusion criteria

Unable to obtain informed consent

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026